| abstract |
The present invention provides new interferon polypeptides of Type 1 coded for by the cDNA inserts of plasmids P9A2 and E76E9 (deposited at the DSM within E.coli HB101 under the numbers DSM 3003 and 3004 respectively), further interferon polypeptides coded for by sequences which will hybridise with the sequences corresponding to the interferon-coding sequences of plasmids P9A2 and E76E9 or degenerate variations thereof under stringent hybridisation conditions suitable for detecting about 85% or higher homology, and N-glycosylated or other derivatives thereof with interferon activity. Such interferons have been designated omega interferons and are useful in treatments in which known interferons have been used, for example, herpes, rhinovirus and AIDS infections as well as certain cancers. |